BAMF Health and GE HealthCare Collaborate on Theranostics

As the demand for Theranostic care grows, GE HealthCare and BAMF Health have entered into a collaboration that will enable BAMF Health to scale turnkey offerings that include leading GE HealthCare technologies and services, ensuring an agile go-to-market approach to accelerate the adoption of Theranostics solutions in the U.S. The agreement supports a shared interest in improving patient outcomes through advanced diagnostics and radiotherapeutics.

Connecting all phases of the Theranostics care pathway, from drug development through disease diagnosis and treatment monitoring, with scalable solutions, connectivity, and advanced imaging technologies, is critical to helping clinicians and health systems bring Theranostics treatments to more patients. The collaboration between GE HealthCare and BAMF Health will leverage both partners’ deep understanding of the complexities of delivering Theranostic care to establish a framework to support the scalable infrastructure and clinical solutions for expanded adoption of precision care.

As the only healthcare industry partner with solutions spanning from cyclotrons, chemistry synthesis, pharmaceutical diagnostics, PET/CT, PET/MR, SPECT/CT, and advanced oncology and digital solutions, GE HealthCare is uniquely positioned to cover the full breadth of the patient care journey. BAMF Health is similarly positioned to advance the practice of Theranostics by utilizing their expertise to partner with health systems across the country to scale molecular imaging and Theranostics, making this new treatment affordable to patients and accessible to clinicians.

To view the source version, please click HERE.